Compare TG Therapeutics Inc (TGTX) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Texas Instruments Incorporated — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.36B), while Texas Instruments Incorporated trades at $258.28 (market cap $238.90B). The key difference: Texas Instruments Incorporated is far larger — about 28.6× TG Therapeutics Inc's market cap, and Texas Instruments Incorporated pays a 2.17% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | TXN | |
|---|---|---|
Market Cap | $8.36B | $238.90B |
Sector | Health | Technology |
52-Week High | $59.06 | $332.35 |
52-Week Low | $26.94 | $153.33 |
Enterprise Value | $8.57B | $245.95B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The stock shows strong profitability with a net income margin of 55.22% and ROE of 100.28%, though recent quarters have seen earnings misses. Revenue growth is robust, with 2026 guidance raised to $950 million for BRIUMVI, and buyout rumors have fueled positive sentiment.
The outlook for TGTX is positive driven by BRIUMVI's commercial success and pipeline catalysts, but risks include earnings volatility, high valuation multiples, and competitive pressures. Institutional accumulation supports upside, yet investors should weigh execution risks against growth potential.
Texas Instruments (TXN) trades at $261.59, up 1.22% with a bearish technical signal. The company reported mixed Q4 2025 earnings but beat expectations in Q1 and Q2 2026. Revenue growth is recovering from 2024 lows, with 2025 revenue at $17.68B and net income of $5.00B. Analyst consensus is bullish with a $329.74 price target, though technical indicators show resistance near $262.
The outlook remains positive with strong profitability margins and AI-driven demand, but risks include rising debt levels and competitive pressures. The stock offers potential upside from current levels if earnings momentum continues, supported by institutional buy ratings and strategic positioning in analog chips.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
